公开(公告)号：US12012431B2

公开(公告)日：2024-06-18

申请号：US18108480

申请日：2023-02-10

申请人： Gilead Sciences, Inc.

发明人： Sankar Mohan

IPC分类号： C07H19/23 ,  C07H1/00

CPC分类号： C07H19/23 ,  C07H1/00

摘要： The present disclosure generally describes methods of preparing 1′-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.

公开(公告)号：US20240174702A1

公开(公告)日：2024-05-30

申请号：US18314989

申请日：2023-05-10

申请人： Gilead Sciences, Inc.

发明人： Ernest A. Carra ,  Lina Chan ,  Roland D. Saito

IPC分类号： C07F9/6558 ,  A61K45/06

CPC分类号： C07F9/65583 ,  A61K45/06 ,  C07B2200/13

摘要： Disclosed herein are solid forms of a compound useful for modulating Cot. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by Cot. The disclosure also relates to methods for obtaining such solid forms.

公开(公告)号：US11976072B2

公开(公告)日：2024-05-07

申请号：US17845534

申请日：2022-06-21

申请人： Gilead Sciences, Inc.

发明人： Julian A. Codelli ,  Michael Graupe ,  Juan A. Guerrero ,  Stephen D. Holmbo ,  Tetsuya Kobayashi ,  Yasamin Moazami ,  Leena B. Patel ,  Heath A. Weaver ,  Jie Xu ,  Suet C. Yeung ,  QingMing Zhu

IPC分类号： C07D487/04 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P35/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

公开(公告)号：US11939347B2

公开(公告)日：2024-03-26

申请号：US17355813

申请日：2021-06-23

申请人： Gilead Sciences, Inc.

发明人： Daniel H. Byun ,  Byoung-Kwon Chun ,  Michael O. Clarke ,  Petr Jansa ,  Rao V. Kalla ,  Dmitry Koltun ,  Richard L. Mackman ,  Thao D. Perry ,  Dustin S. Siegel ,  Scott P. Simonovich

IPC分类号： A61K31/675 ,  A61K45/06 ,  A61P31/12 ,  C07F9/6561

CPC分类号： C07F9/6561 ,  A61K45/06

摘要： Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

公开(公告)号：US20240091351A1

公开(公告)日：2024-03-21

申请号：US18469844

申请日：2023-09-19

申请人： Gilead Sciences, Inc.

发明人： Hikmat H. Assi ,  Jamie G. Bates

IPC分类号： A61K39/395 ,  A61N5/10 ,  A61P35/00

CPC分类号： A61K39/3955 ,  A61N5/10 ,  A61P35/00 ,  A61K2039/545

摘要： Provided are methods of treating, mitigating, reducing, preventing or delaying the growth, proliferation, recurrence or metastasis of a solid cancer in a mammalian subject in need thereof comprising co-administering to the subject an effective amount of radiation therapy (RT) focally-delivered to the solid cancer; and an agent that inhibits binding between CD47 and SIRPα.

公开(公告)号：US20240091251A1

公开(公告)日：2024-03-21

申请号：US18241303

申请日：2023-09-01

申请人： Gilead Sciences, Inc.

发明人： Nate Larson ,  Robert G. Strickley

IPC分类号： A61K31/724 ,  A61K9/00 ,  A61K9/19 ,  A61K31/683 ,  A61K47/40 ,  A61K47/69 ,  A61P31/12

CPC分类号： A61K31/724 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/683 ,  A61K47/40 ,  A61K47/6951 ,  A61P31/12

摘要： The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

公开(公告)号：US11931424B2

公开(公告)日：2024-03-19

申请号：US17836480

申请日：2022-06-09

申请人： Gilead Sciences, Inc.

发明人： Thomas F. Kenney ,  Clinton K. Matson ,  Chandrasekar Venkataramani

IPC分类号： A61K47/68 ,  A61K31/519 ,  A61K31/553 ,  A61P11/00 ,  A61P35/00 ,  A61P35/04

CPC分类号： A61K47/6851 ,  A61K31/519 ,  A61K31/553 ,  A61K47/6803 ,  A61P11/00 ,  A61P35/00 ,  A61P35/04

摘要： The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.

公开(公告)号：US11926645B2

公开(公告)日：2024-03-12

申请号：US17458023

申请日：2021-08-26

申请人： Gilead Sciences, Inc.

发明人： Elaine Bunyan ,  Byoung-Kwon Chun ,  Kassibla E. Dempah ,  Hon C. Hui ,  Rao V. Kalla ,  Richard L. Mackman

IPC分类号： C07H7/06 ,  A61P31/12

CPC分类号： C07H7/06 ,  A61P31/12 ,  C07B2200/13

摘要： Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

公开(公告)号：US11926628B2

公开(公告)日：2024-03-12

申请号：US17844871

申请日：2022-06-21

申请人： Gilead Sciences, Inc.

发明人： Julian A. Codelli ,  Michael Graupe ,  Juan A. Guerrero ,  Jesse M. Jacobsen ,  Tetsuya Kobayashi ,  Jonathan William Medley ,  Yasamin Moazami ,  Leena B. Patel ,  Jie Xu ,  Suet C. Yeung

IPC分类号： C07D471/14 ,  A61K31/519

CPC分类号： C07D471/14

摘要： The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

公开(公告)号：USD1016608S1

公开(公告)日：2024-03-05

申请号：US29837856

申请日：2022-05-09

申请人： Gilead Sciences, Inc.

设计人： Benjamin Luke Kozub ,  Brian Nilstoft ,  Kevin Nguyen ,  James Paul Oberhauser ,  Roman Shumylo ,  Joseph Anthony Cordova ,  Jinhui Yun ,  William Harold Lizor, Jr. ,  Adam Hilborn ,  Jesse Arnold Fourt ,  Léo Boris Marzolf ,  Pratap Uday Ganapathy ,  Brooke Genelle Thyng ,  Caricia Catalani ,  Soizic Porhel ,  Jose Angel Meza ,  Steven M. Scally ,  Mary Cassandra Lodwick

摘要： FIG. 1 is a front top perspective view of a pharmaceutical package in an open configuration;
FIG. 2 is a back bottom perspective view thereof;
FIG. 3 is front view thereof;
FIG. 4 is a back view thereof;
FIG. 5 is left side view thereof;
FIG. 6 is right side view thereof;
FIG. 7 is top view thereof;
FIG. 8 is bottom view thereof;
FIG. 9 is a front top perspective view of the pharmaceutical package in a partially folded configuration;
FIG. 10 is a back bottom perspective view thereof;
FIG. 11 is front view thereof;
FIG. 12 is a back view thereof;
FIG. 13 is left side view thereof;
FIG. 14 is right side view thereof;
FIG. 15 is top view thereof;
FIG. 16 is bottom view thereof;
FIG. 17 is a front bottom perspective view of the pharmaceutical package in a fully folded configuration;
FIG. 18 is a back top perspective view thereof;
FIG. 19 is left side view thereof;
FIG. 20 is a right side view thereof;
FIG. 21 is front view thereof;
FIG. 22 is back view thereof;
FIG. 23 is top view thereof; and,
FIG. 24 is bottom view thereof.
The dashed lines in the drawings depict portions of the pharmaceutical package that form no part of the claimed design. The dot-dash lines in the drawings depict the boundaries of the claim and form no part thereof.
The gray shading in the figures depicts a contrast of appearance.